LUNG

PulmonxC

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.40

+57.9% vs current

Most likely

Base case

45%

Probability

Target price

$1.00

-34.2% vs current

B-

Bear case

30%

Probability

Target price

$0.50

-67.1% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

This remains a cautious monitoring memo, not a confirmed post-earnings thesis change. As of April 29, 2026 UTC, Pulmonx's investor-relations news page still showed the April 15 scheduling release rather than posted Q1 2026 results, and the company SEC-filings page showed no newer earnings filing than the March 2026 items checked here. That means earnings surprise, analyst revisions, and immediate post-print price reaction were unavailable for confirmation in this T+1 run, so the deterministic negative prior still carries more weight than narrative hope.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-29eventQ1 2026 earnings release is the immediate unresolved swing factorHigh impact

Pulmonx said on April 15, 2026 that it would report first-quarter 2026 financial results after the close on April 29, 2026, but as of the company pages checked for this run the result itself was not yet posted, leaving revenue, cash-burn trajectory, guidance confirmation, and the first market read-through unconfirmed [#IR-2026-04-15].

2026-12-31catalystFlat 2026 outlook and financing terms keep balance-sheet pressure front and centerHigh impact

Pulmonx guided 2026 revenue to $90 million-$92 million versus $90.5 million in 2025, expects about $23 million of cash usage in 2026 absent extra drawdowns, and refinanced with a Perceptive facility whose undrawn tranches depend on revenue milestones; that leaves little room for a commercial miss before financing risk becomes the dominant equity narrative [#PR-2026-03-04] [#8-K-2026-03-05] [#10-K-2026-03-10].

2026-12-31catalystZephyr adoption and U.S. reacceleration remain the only clean path to a reratingHigh impact

Management framed 2025 as a transition year and said the operating plan is aimed at reaccelerating commercial growth while advancing the clinical pipeline; the underlying setup is still a concentrated Zephyr story, with fourth-quarter 2025 U.S. revenue down 11% year over year even as international revenue grew 8%, so a durable rerating still requires proof that procedure demand and hospital adoption can improve in the core business [#PR-2026-03-04] [#10-K-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology